Is Apparent Diffusion Coeffi cient Associated with Clinical Risk Scores for Prostate Cancers that Are Visible on 3-T MR Images ? 1

To investigate whether apparent diffusion coefficients (ADCs) derived from diffusion-weighted (DW) magnetic resonance (MR) imaging at 3 T correlate with the clinical risk of prostate cancer in patients with tumors that are visible on MR images, with MR imaging/transrectal ultra-sonography (US) fusion–guided biopsy as a reference. in institutional and informed was obtained from each Patients underwent targeted imaging/transrectal US fusion–guided prostate biopsy. Mean ADCs of cancerous target tumors were correlated with Gleason and D’Amico clinical risk scores. The true risk group rate and predictive value of the mean ADC for classifying a tumor by its D’Amico clinical risk score was determined by using

[1]  J. Machan,et al.  Diffusion-weighted MRI of peripheral zone prostate cancer: comparison of tumor apparent diffusion coefficient with Gleason score and percentage of tumor on core biopsy. , 2010, AJR. American journal of roentgenology.

[2]  A. Prando.  Prostate tumor volume measurement with combined T2-weighted imaging and diffusion-weighted MR: correlation with pathologic tumor volume , 2009 .

[3]  A. Thompson,et al.  MRI in the detection of prostate cancer: combined apparent diffusion coefficient, metabolite ratio, and vascular parameters. , 2009, AJR. American journal of roentgenology.

[4]  Gary P Liney,et al.  Correlation of ADC and T2 Measurements With Cell Density in Prostate Cancer at 3.0 Tesla , 2009, Investigative radiology.

[5]  Jason A Koutcher,et al.  Prostate tumor volume measurement with combined T2-weighted imaging and diffusion-weighted MR: correlation with pathologic tumor volume. , 2009, Radiology.

[6]  T. Tammela,et al.  Gleason score 7 screen‐detected prostate cancers initially managed expectantly: outcomes in 50 men , 2009, BJU international.

[7]  Bin Wang,et al.  Diffusion‐weighted imaging of prostate cancer: Correlation between apparent diffusion coefficient values and tumor proliferation , 2009, Journal of magnetic resonance imaging : JMRI.

[8]  Gary Liney,et al.  Correlation of diffusion‐weighted magnetic resonance data with cellularity in prostate cancer , 2009, BJU international.

[9]  P. Choyke,et al.  Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations. , 2009, Neoplasia.

[10]  P. Albertsen,et al.  Outcomes following active surveillance of men with localized prostate cancer diagnosed in the prostate specific antigen era. , 2008, The Journal of urology.

[11]  Katsuyoshi Ito,et al.  Apparent diffusion coefficient values in peripheral and transition zones of the prostate: Comparison between normal and malignant prostatic tissues and correlation with histologic grade , 2008, Journal of magnetic resonance imaging : JMRI.

[12]  N M deSouza,et al.  Diffusion-weighted magnetic resonance imaging: a potential non-invasive marker of tumour aggressiveness in localized prostate cancer. , 2008, Clinical radiology.

[13]  M. Cooperberg,et al.  Active surveillance for the management of prostate cancer in a contemporary cohort , 2008, Cancer.

[14]  D. Dearnaley,et al.  Correlation of diffusion-weighted MRI with whole mount radical prostatectomy specimens. , 2008, The British journal of radiology.

[15]  P. Choyke,et al.  Real-time MRI-TRUS fusion for guidance of targeted prostate biopsies , 2008, Computer aided surgery : official journal of the International Society for Computer Aided Surgery.

[16]  Benjamin M Yeh,et al.  Peripheral zone prostate cancer: accuracy of different interpretative approaches with MR and MR spectroscopic imaging. , 2008, Radiology.

[17]  H. Hricak,et al.  Assessment of biologic aggressiveness of prostate cancer: correlation of MR signal intensity with Gleason grade after radical prostatectomy. , 2008, Radiology.

[18]  L. Turnbull,et al.  Repeatability of echo-planar-based diffusion measurements of the human prostate at 3 T. , 2007, Magnetic resonance imaging.

[19]  Tristan Barrett,et al.  Dynamic contrast-enhanced MRI of prostate cancer at 3 T: a study of pharmacokinetic parameters. , 2007, AJR. American journal of roentgenology.

[20]  Thomas Hambrock,et al.  Prostate cancer: body-array versus endorectal coil MR imaging at 3 T--comparison of image quality, localization, and staging performance. , 2007, Radiology.

[21]  B. K. Park,et al.  Comparison of Phased-Array 3.0-T and Endorectal 1.5-T Magnetic Resonance Imaging in the Evaluation of Local Staging Accuracy for Prostate Cancer , 2007, Journal of computer assisted tomography.

[22]  V. Pansadoro,et al.  Contribution of the MR spectroscopic imaging in the diagnosis of prostate cancer in the peripheral zone , 2007, Abdominal Imaging.

[23]  M. Kenward,et al.  An Introduction to the Bootstrap , 2007 .

[24]  H. Huisman,et al.  Prostate cancer localization with dynamic contrast-enhanced MR imaging and proton MR spectroscopic imaging. , 2006, Radiology.

[25]  T. H. van der Kwast,et al.  Management and survival of screen-detected prostate cancer patients who might have been suitable for active surveillance. , 2006, European urology.

[26]  M. Kattan,et al.  Preoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. , 2006, Journal of the National Cancer Institute.

[27]  C. Kim,et al.  Localization of Prostate Cancer Using 3T MRI: Comparison of T2-Weighted and Dynamic Contrast-Enhanced Imaging , 2006, Journal of computer assisted tomography.

[28]  J Alfred Witjes,et al.  Staging prostate cancer with dynamic contrast-enhanced endorectal MR imaging prior to radical prostatectomy: experienced versus less experienced readers. , 2005, Radiology.

[29]  Charles E. Heckler,et al.  Applied Multivariate Statistical Analysis , 2005, Technometrics.

[30]  P. Walsh,et al.  Radical prostatectomy versus watchful waiting in early prostate cancer. , 2005, The Journal of urology.

[31]  L. Klotz.  Active surveillance for good risk prostate cancer: rationale, method, and results. , 2005, The Canadian journal of urology.

[32]  C. Goose,et al.  Glossary of Terms , 2004, Machine Learning.

[33]  A W Partin,et al.  Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium. , 2002, Urology.

[34]  S B Malkowicz,et al.  Biochemical Outcome After Radical Prostatectomy , External Beam Radiation Therapy , or Interstitial Radiation Therapy for Clinically Localized Prostate Cancer , 2000 .

[35]  P. Carroll,et al.  Three-dimensional H-1 MR spectroscopic imaging of the in situ human prostate with high (0.24-0.7-cm3) spatial resolution. , 1996, Radiology.